Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/16905
Title: Terlipressin: current and emerging indications in chronic liver disease
Authors: Papaluca, Timothy;Gow, Paul J
Issue Date: Mar-2018
EDate: 2017-10-05
Citation: Journal of Gastroenterology and Hepatology 2018; 33(3): 591-598
Abstract: Terlipressin is an analogue of vasopressin that has potent vasoactive properties and has been available for use in most countries for nearly two decades. It has both established roles and emerging indications in the management of complications of decompensated chronic liver disease. We explore historic and emerging literature regarding the use of terlipressin for a range of indications including hepatorenal syndrome, portal hypertensive bleeding and disruptions in sodium homeostasis. Novel methods of infusion based terlipressin administration including the beneficial effect in reduction of adverse events are explored, in addition to new indications for the use of terlipressin in decompensated cirrhosis in an outpatient setting.
URI: http://ahro.austin.org.au/austinjspui/handle/1/16905
DOI: 10.1111/jgh.14009
PubMed URL: https://www.ncbi.nlm.nih.gov/pubmed/28981166
Type: Journal Article
Subjects: Hepatorenal syndrome
Terlipressin
cirrhosis
portal hypertension
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.